Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;182(2):266.
doi: 10.1111/bjd.18717. Epub 2019 Dec 15.

Noninferiority of biosimilar MSB110222 to reference adalimumab for chronic plaque psoriasis

Affiliations
Comment

Noninferiority of biosimilar MSB110222 to reference adalimumab for chronic plaque psoriasis

R G Borroni et al. Br J Dermatol. 2020 Feb.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

References

    1. Sarpatwari A, Barenie R, Curfman G et al. The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther 2019; 105:92-100.
    1. Blauvelt A, Cohen AD, Puig L et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol 2016; 174:282-6.
    1. U.S. Department of Health and Human Services, Food and Drug Administration. Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations. May 2019. Available at: https://www.fda.gov/media/125484/download (last accessed 13 November 2019).
    1. Hercogová J, Papp KA, Chyrok V et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 2020; 182:316-26.
    1. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 2015; 29:645-8.

Publication types